ERBB2 and breast cancer: Similarly, Turashvili et al. further investigated the relationship between 21-gene RS and LRR risk among 2326 patients with node-negative ER + /HER2- breast cancer who were treated at the Memorial Sloan Kettering Cancer Center from 2008 to 2013 [16].